Plk1 — Drug Target
All drugs that target Plk1 — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Phase 3 pipeline (1)
- Utidelone plus Intermittent Capecitabine · Sun Yat-sen University · Plk1 inhibitor · Oncology
Utidelone is a novel, orally administered, small molecule inhibitor of the polo-like kinase 1 (Plk1), which plays a critical role in cell cycle progression and is overexpressed in various cancers.